German price cuts loom for Novartis' Galvus and Merck's Januvia
This article was originally published in Scrip
Executive Summary
Novartis and Merck could soon have to drop the prices of their DPP-4 inhibitors, vildagliptin and sitagliptin, in Germany if health technology appraisal bodies there remain less than impressed. The products are undergoing the first retrospective review under Germany's tough AMNOG pricing and reimbursement system and IQWiG, the Institute for Quality and Efficiency and Healthcare, has just released the preliminary findings.